Pipeline and Commercial Perspectives: Insomnia

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2005-12-21

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Until recently, the insomnia market has been dominated by Ambien, Sonata, and Imovane, and the older hypnotics such as benzodiazepines. However, the global insomnia market is set to grow from $3.7 billion in 2005 to $5.5 billion by 2014 (CAGR, 5.6% 200514), driven primarily by the launch and up-take of Lunesta, Rozerem and Ambien CR as well as pipeline drugs from 2006 onwards.


Scope

  • Overview of current market including profiles of key brands and key events impacting each brand during 2004-2005
  • Assessment of current and future opportunities and threats in the insomnia market in the US, EU and Japanese pharmaceutical markets
  • Examination of the hypnotics pipeline with in-depth clinical and commercial profiles of late-stage candidates, with Datamonitor and KOL opinions
  • In-depth discussion of assumptions and events used in forecast analysis


    • Report Highlights
    Ambien with US revenues of $2 billion in 2004 faces competition from recently launched hypnotics, and will experience genericization from 2006. Sanofi-Aventis launched Ambien CR in the US during October 2005, although Datamonitor forecasts that the Ambien franchise will decline from 2006 onwards to approximately half the value it is today by 2014.

    By 2014, prospective players can expect to face stiff competition from numerous generics, worth nearly $800m, as well as a number of non-GABA A, non-scheduled hypnotics with revenues topping $700m. In such a crowded market, innovation is key and product differentiation, demonstration of cost-effectiveness and niche strategies are essential.

    The transient insomnia market is severely under served, and presents an ideal niche for manufacturers. If manufacturers can increase the proportion of individuals using prescription hypnotics at least a few nights a month, to the level of those who use them at least a few times a week, usage of prescription hypnotics could increase by 50%.


    Reasons to Purchase

  • Understand the challenge faced by established hypnotics by the emergence of generic competition
  • Develop strategies to grow the value of niche patient groups, such as the transient insomnia market
  • Benchmark recently launched and pipeline hypnotics against Ambien and assess their future market potential

    • Table of Contents

    Other users found this report page using the following search terms: insomnia sleep disorders insomnia market eplivanserin drugs ambien lunesta pipeline launch sleep patent

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.